Wim J G Oyen

List of Publications by Year
in descending order

519 papers	33,723 citations	4136 87 h-index	6128 159 g-index
532 all docs	532 docs citations	532 times ranked	31792 citing authors

#	Article	IF	Citations
1	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	0.6	2,545
2	FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 328-354.	3.3	2,188
3	FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 181-200.	3.3	1,147
4	Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nature Biotechnology, 2005, 23, 1407-1413.	9.4	791
5	Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Research, 2003, 63, 12-7.	0.4	659
6	Gender differences in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 819-824.	0.9	554
7	Peritoneal Carcinomatosis of Colorectal Origin. Annals of Surgery, 2006, 243, 212-222.	2.1	442
8	Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2004-2010.	3.3	394
9	Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood, 2001, 98, 1802-1811.	0.6	383
10	Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Annals of Neurology, 2011, 69, 269-281.	2.8	348
11	The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2320-2333.	3.3	343
12	A Prospective Multicenter Study on Fever of Unknown Origin. Medicine (United States), 2007, 86, 26-38.	0.4	321
13	Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18Fâ€“DOPA. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1588-1601.	3.3	319
14	Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients. Cancer Research, 2013, 73, 1063-1075.	0.4	295
15	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Annals of Oncology, 2016, 27, 619-624.	0.6	269
16	Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 392-404.	3.3	268
17	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
18	Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention. Journal of Nuclear Medicine, 2010, 51, 1049-1058.	2.8	245

#	Article	IF	Citations
19	Imaging of Inflammation by PET, Conventional Scintigraphy, and Other Imaging Techniques. Journal of Nuclear Medicine, 2010, 51, 1937-1949.	2.8	231
20	Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 29-37.	3.3	230
21	The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer, 2005, 104, 2658-2670.	2.0	228
22	The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1932-1947.	3.3	228
23	PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 55-69.	3.3	200
24	Monitoring and Predicting Response to Therapy with ¹⁸F-FDG PET in Colorectal Cancer: A Systematic Review. Journal of Nuclear Medicine, 2009, 50, 43S-54S.	2.8	197
25	Improved targeting of the Î±vÎ²3 integrin by multimerisation of RGD peptides. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 267-273.	3.3	195
26	A Novel Facile Method of Labeling Octreotide with ¹⁸F-Fluorine. Journal of Nuclear Medicine, 2010, 51, 454-461.	2.8	193
27	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Antiâ€“PD-L1 Antibodies. Cancer Research, 2015, 75, 2928-2936.	0.4	193
28	Reflex sympathetic dystrophy of the hand: an excessive inflammatory response?. Pain, 1993, 55, 151-157.	2.0	187
29	PET and SPECT in Osteomyelitis and Prosthetic Bone and Joint Infections: A Systematic Review. Seminars in Nuclear Medicine, 2010, 40, 3-15.	2.5	185
30	Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy. European Urology, 2010, 58, 75-83.	0.9	183
31	A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 694-703.	3.3	182
32	Spatial Resolution and Sensitivity of the Inveon Small-Animal PET Scanner. Journal of Nuclear Medicine, 2009, 50, 139-147.	2.8	175
33	Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer, 2007, 55, 79-87.	0.9	174
34	Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients. Clinical Cancer Research, 2009, 15, 2531-2540.	3.2	172
35	Improved Selection of Patients for Hepatic Surgery of Colorectal Liver Metastases with ¹⁸F-FDG PET: A Randomized Study. Journal of Nuclear Medicine, 2009, 50, 1036-1041.	2.8	171
36	111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1441-1448.	3.3	158

#	Article	IF	Citations
37	Route of Administration Modulates the Induction of Dendritic Cell Vaccineâ€“Induced Antigen-Specific T Cells in Advanced Melanoma Patients. Clinical Cancer Research, 2011, 17, 5725-5735.	3.2	158
38	Imaging infection/inflammation in the new millennium. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 241-252.	2.2	156
39	Pretargeted radioimmunotherapy of cancer: progress step by step. Journal of Nuclear Medicine, 2003, 44, 400-11.	2.8	155
40	Comparison of a Monomeric and Dimeric Radiolabeled RGD-Peptide for Tumor Targeting. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 641-646.	0.7	153
41	Fluorinated amino acids for tumour imaging with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 681-690.	3.3	153
42	Indication for Different Mechanisms of Kidney Uptake of Radiolabeled Peptides. Journal of Nuclear Medicine, 2007, 48, 596-601.	2.8	150
43	¹⁸F-FLT PET/CT for Early Response Monitoring and Dose Escalation in Oropharyngeal Tumors. Journal of Nuclear Medicine, 2010, 51, 866-874.	2.8	147
44	18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients. Journal of Nuclear Medicine, 2007, 48, 726-735.	2.8	142
45	Predictive and prognostic value of FDGâ€PET in nonsmallâ€cell lung cancer. Cancer, 2007, 110, 1654-1664.	2.0	141
46	Image-Quality Assessment for Several Positron Emitters Using the NEMA NU 4-2008 Standards in the Siemens Inveon Small-Animal PET Scanner. Journal of Nuclear Medicine, 2010, 51, 610-617.	2.8	138
47	The role of 18fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU International, 2002, 89, 549-556.	1.3	135
48	The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 761-767.	0.5	134
49	Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin. Diabetologia, 2014, 57, 950-959.	2.9	129
50	Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncology, The, 2021, 22, e136-e172.	5.1	129
51	Clinical radionuclide therapy dosimetry: the quest for the â€œHoly Grayâ€. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 772-786.	3.3	127
52	Managing Nonmetastatic Castration-resistant Prostate Cancer. European Urology, 2019, 75, 285-293.	0.9	125
53	68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1345-1355.	3.3	124
54	Normal Bone Mineral Density and Lean Body Mass, but Increased Fat Mass, in Young Adult Patients with Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1036-1042.	1.8	122

#	Article	IF	Citations
55	¹⁸F-FDG PET/CT for Detection of Metastatic Infection in Gram-Positive Bacteremia. Journal of Nuclear Medicine, 2010, 51, 1234-1240.	2.8	121
56	Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Annals of Hematology, 2009, 88, 1161-1168.	0.8	120
57	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. International Journal of Cancer, 2011, 129, 507-512.	2.3	120
58	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 2021, 146, 56-73.	1.3	120
59	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 469-476.	3.3	119
60	Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in Children. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1593-1600.	2.2	117
61	Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 98-101.	3.3	116
62	¹⁸F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome. Journal of Nuclear Medicine, 2013, 54, 532-540.	2.8	111
63	Fever of Unknown Origin: the Value of FDG-PET/CT. Seminars in Nuclear Medicine, 2018, 48, 100-107.	2.5	110
64	Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 2007, 48, 1592-1598.	2.8	109
65	Methodological considerations in quantification of oncological FDG PET studies. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1408-1425.	3.3	108
66	Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 623-632.	3.3	108
67	PET imaging of Î±vÎ²3 integrin expression in tumours with 68Ga-labelled mono-, di- and tetrameric RGD peptides. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 128-137.	3.3	107
68	Glucose Metabolism in NSCLC Is Histology-Specific and Diverges the Prognostic Potential of 18FDG-PET for Adenocarcinoma and Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2014, 9, 1485-1493.	0.5	107
69	A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nuclear Medicine Communications, 2007, 28, 485-493.	0.5	106
70	PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncology, The, 2010, 11, 661-669.	5.1	105
71	¹⁸F-FDG PET Early Response Evaluation of Locally Advanced Nonâ€“Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy. Journal of Nuclear Medicine, 2013, 54, 1528-1534.	2.8	104
72	EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 412-422.	3.3	104

#	Article	IF	Citations
73	Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients. BioMed Research International, 2014, 2014, 1-13.	0.9	103
74	Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1419, 325-334.	1.4	101
75	FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 399-404.	3.3	100
76	Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. Journal of Nuclear Medicine, 2004, 45, 327-37.	2.8	99
77	PET of Hypoxia with⁸⁹Zr-Labeled cG250-F(abâ€²)₂in Head and Neck Tumors. Journal of Nuclear Medicine, 2010, 51, 1076-1083.	2.8	98
78	A systematic review on [18F]FLT-PET uptake as a measure of treatment response in cancer patients. European Journal of Cancer, 2016, 55, 81-97.	1.3	98
79	Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial. Radiotherapy and Oncology, 2008, 87, 221-229.	0.3	97
80	Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation. Lung Cancer, 2012, 75, 73-76.	0.9	97
81	Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study. Theranostics, 2018, 8, 2161-2170.	4.6	97
82	Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases, 2003, 41, e22.1-e22.4.	2.1	96
83	2-(18F)-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Detects Clinical Relevant Adenomas of the Colon: A Prospective Study. Journal of Clinical Oncology, 2005, 23, 3713-3717.	0.8	92
84	Scintigraphic Techniques for Early Detection of Cancer Treatmentâ€“Induced Cardiotoxicity. Journal of Nuclear Medicine, 2011, 52, 560-571.	2.8	92
85	Prospective Comparison of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Patients With Melanoma With Palpable Lymph Node Metastases: Diagnostic Accuracy and Impact on Treatment. Journal of Clinical Oncology, 2009, 27, 4774-4780.	0.8	91
86	Metastatic Infectious Disease and Clinical Outcome in Staphylococcus aureus and Streptococcus species Bacteremia. Medicine (United States), 2012, 91, 86-94.	0.4	91
87	A comparison of the diagnostic value of MRI and 18F-FDG-PET/CT in suspected spondylodiscitis. Infection, 2017, 45, 41-49.	2.3	90
88	Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708.	5.1	90
89	Clinical evidence on PETâ€“CT for radiation therapy planning in head and neck tumours. Radiotherapy and Oncology, 2010, 96, 328-334.	0.3	88
90	Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1410-1416.	3.3	88

#	Article	IF	Citations
91	The EANM practical guidelines for sentinel lymph node localisation in oral cavity squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 623-637.	3.3	88
92	Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1273-1279.	3.3	85
93	Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1803-1811.	3.3	85
94	Pretargeted Immunoâ€“Positron Emission Tomography Imaging of Carcinoembryonic Antigenâ€“Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts. Molecular Cancer Therapeutics, 2010, 9, 1019-1027.	1.9	85
95	Commonly Used Imaging Techniques for Diagnosis and Staging. Journal of Clinical Oncology, 2006, 24, 3234-3244.	0.8	84
96	Fever of Unknown Origin. Seminars in Nuclear Medicine, 2009, 39, 81-87.	2.5	84
97	ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model. Journal of Nuclear Medicine, 2010, 51, 1565-1572.	2.8	84
98	Cost-Effectiveness of Routine¹⁸F-FDG PET/CT in High-Risk Patients with Gram-Positive Bacteremia. Journal of Nuclear Medicine, 2011, 52, 1673-1678.	2.8	84
99	Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Antiâ€“Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis. Journal of Nuclear Medicine, 2015, 56, 778-783.	2.8	84
100	In Vivo Imaging of Abdominal Aortic Aneurysms:Increased FDG Uptake Suggests Inflammation in the Aneurysm Wall. Journal of Endovascular Therapy, 2008, 15, 462-467.	0.8	83
101	The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1463-1477.	3.3	83
102	Nuclear medicine imaging to predict response to radiotherapy: a review. International Journal of Radiation Oncology Biology Physics, 2003, 55, 5-15.	0.4	82
103	Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2005, 23, 6540-6548.	0.8	80
104	The role of [¹⁸F]â€2â€fluoroâ€2â€deoxyâ€dâ€glucoseâ€“positron emission tomography in thyroid nodules with indeterminate fineâ€needle aspiration biopsy. Cancer, 2011, 117, 4582-4594.	2.0	79
105	Reducing Renal Uptake of Radiolabeled Peptides Using Albumin Fragments. Journal of Nuclear Medicine, 2008, 49, 1506-1511.	2.8	78
106	Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody. Journal of Nuclear Medicine, 2014, 55, 995-1001.	2.8	78
107	The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1102-1107.	3.3	77
108	Radiopharmaceuticals to image infection and inflammation. Seminars in Nuclear Medicine, 2001, 31, 286-295.	2.5	76

#	Article	IF	Citations
109	Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nuclear Medicine and Biology, 2007, 34, 29-35.	0.3	76
110	Liposomes for scintigraphic detection of infection and inflammation. Advanced Drug Delivery Reviews, 1999, 37, 225-235.	6.6	75
111	PETâ€“CT for radiotherapy treatment planning and response monitoring in solid tumors. Nature Reviews Clinical Oncology, 2011, 8, 233-242.	12.5	75
112	PET in the management of locally advanced and metastatic NSCLC. Nature Reviews Clinical Oncology, 2015, 12, 395-407.	12.5	75
113	EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 616-622.	3.3	74
114	Innovations in Radiotherapy Planning of Head and Neck Cancers: Role of PET. Journal of Nuclear Medicine, 2010, 51, 66-76.	2.8	73
115	Imaging hypoxia after oxygenation-modification: Comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiotherapy and Oncology, 2006, 80, 157-164.	0.3	72
116	18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1131-1137.	3.3	72
117	Optimized labeling of NOTA-conjugated octreotide with F-18. Tumor Biology, 2012, 33, 427-434.	0.8	72
118	Radiolabelled peptides for oncological diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 78-92.	3.3	71
119	Phase 1 Radioimmunotherapy Study with Lutetium 177â€“labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. European Urology, 2013, 64, 478-485.	0.9	71
120	18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. Journal of Nuclear Medicine, 2006, 47, 770-5.	2.8	71
121	Comparison of Multiphase CT, FDG-PET and Intra-Operative Ultrasound in Patients with Colorectal Liver Metastases Selected for Surgery. Annals of Surgical Oncology, 2007, 14, 818-826.	0.7	70
122	Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1449-1458.	3.3	70
123	¹⁸F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality. Journal of Nuclear Medicine, 2017, 58, 1504-1510.	2.8	70
124	Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. Journal of Nuclear Medicine, 2006, 47, 945-9.	2.8	70
125	Indium-111â€“labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma. European Urology, 2013, 63, 1101-1106.	0.9	69
126	A Curve-Fitting Approach to Estimate the Arterial Plasma Input Function for the Assessment of Glucose Metabolic Rate and Response to Treatment. Journal of Nuclear Medicine, 2009, 50, 1933-1939.	2.8	68

#	Article	IF	Citations
127	The Impact of Optimal Respiratory Gating and Image Noise on Evaluation of Intratumor Heterogeneity on ¹⁸F-FDG PET Imaging of Lung Cancer. Journal of Nuclear Medicine, 2016, 57, 1692-1698.	2.8	67
128	The diagnostic value of 18Fâ€“FDG-PET/CT and MRI in suspected vertebral osteomyelitis â€“ a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 798-805.	3.3	67
129	Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer. Journal of Nuclear Medicine, 2012, 53, 146-153.	2.8	66
130	PET and SPECT Imaging of a Radiolabeled Minigastrin Analogue Conjugated with DOTA, NOTA, and NODAGA and Labeled with ⁶⁴Cu, ⁶⁸Ga, and ¹¹¹In. Molecular Pharmaceutics, 2014, 11, 3930-3937.	2.3	66
131	Caffeine Prevents Protection in Two Human Models of Ischemic Preconditioning. Journal of the American College of Cardiology, 2006, 48, 700-707.	1.2	65
132	Early identification of antigen-specific immune responses in vivo by [¹⁸ F]-labeled 3â€²-fluoro-3â€²-deoxy-thymidine ([¹⁸ F]FLT) PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18396-18399.	3.3	65
133	PET of Tumors Expressing Gastrin-Releasing Peptide Receptor with an ¹⁸F-Labeled Bombesin Analog. Journal of Nuclear Medicine, 2012, 53, 947-952.	2.8	65
134	Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. European Urology, 2018, 74, 257-260.	0.9	65
135	Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. Journal of Nuclear Medicine, 2006, 47, 528-33.	2.8	63
136	PET Radioimmunoscintigraphy of Renal Cell Cancer Using 89Zr-Labeled cG250 Monoclonal Antibody in Nude Rats. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 155-163.	0.7	62
137	Comparison Between Local Ablative Therapy and Chemotherapy for Non-Resectable Colorectal Liver Metastases: A Prospective Study. Annals of Surgical Oncology, 2007, 14, 1161-1169.	0.7	62
138	Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. Journal of Nuclear Medicine, 2006, 47, 432-6.	2.8	62
139	Radio-labeled receptor-binding peptides: A new class of radiopharmaceuticals. Seminars in Nuclear Medicine, 2000, 30, 195-208.	2.5	61
140	Î±vÎ²3 Integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. International Journal of Cancer, 2007, 120, 605-610.	2.3	61
141	Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?. Critical Reviews in Oncology/Hematology, 2012, 83, 194-207.	2.0	61
142	In Vivo Applications of PEG Liposomes: Unexpected Observations. Critical Reviews in Therapeutic Drug Carrier Systems, 2001, 18, 16.	1.2	61
143	Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's Disease. Journal of Drug Targeting, 2000, 8, 225-233.	2.1	60
144	Specific imaging of VEGFâ€A expression with radiolabeled antiâ€VEGF monoclonal antibody. International Journal of Cancer, 2008, 122, 2310-2314.	2.3	59

#	Article	IF	Citations
145	Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. European Journal of Cancer, 2008, 44, 1835-1840.	1.3	59
146	Imaging the Folate Receptor on Cancer Cells with ^{99m}Tc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging. Journal of Nuclear Medicine, 2014, 55, 701-704.	2.8	59
147	F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. Intensive Care Medicine, 2010, 36, 504-511.	3.9	58
148	Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. NeuroImage, 2012, 59, 3339-3346.	2.1	58
149	Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. Clinical Cancer Research, 2013, 19, 1525-1533.	3.2	58
150	FDG-PET in Fever of Unknown Origin. Seminars in Nuclear Medicine, 2013, 43, 333-339.	2.5	57
151	Phase 2 Study of Lutetium 177â€“Labeled Antiâ€“Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. European Urology, 2016, 69, 767-770.	0.9	57
152	In situ Expression of Tumor Antigens by Messenger RNAâ€“Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients. Cancer Research, 2009, 69, 2927-2934.	0.4	56
153	18F-FDG PET in detecting metastatic infectious disease. Journal of Nuclear Medicine, 2005, 46, 2014-9.	2.8	56
154	Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocrine-Related Cancer, 2006, 13, 1203-1211.	1.6	55
155	Modelling and simulation of [18F]fluoromisonidazole dynamics based on histology-derived microvessel maps. Physics in Medicine and Biology, 2011, 56, 2045-2057.	1.6	54
156	A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. Thyroid, 2021, 31, 1009-1019.	2.4	54
157	Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a headâ€andâ€neck squamous cell carcinoma model. International Journal of Cancer, 2011, 129, 870-878.	2.3	53
158	Theranostic applications of antibodies in oncology. Molecular Oncology, 2014, 8, 799-812.	2.1	53
159	Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry. Frontiers in Medicine, 2014, 1, 44.	1.2	53
160	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1931-1939.	3.3	53
161	Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. Journal of Nuclear Medicine, 2004, 45, 1224-32.	2.8	53
162	Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. Surgery, 2005, 137, 246-249.	1.0	52

#	Article	IF	Citations
163	Predictive and prognostic value of FDG-PET. Cancer Imaging, 2008, 8, 70-80.	1.2	52
164	Antibody-guided radiation therapy of cancer. Cancer and Metastasis Reviews, 2005, 24, 539-567.	2.7	51
165	Comparison of Tumor Volumes Derived from Glucose Metabolic Rate Maps and SUV Maps in Dynamic ¹⁸F-FDG PET. Journal of Nuclear Medicine, 2008, 49, 892-898.	2.8	51
166	Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. European Radiology, 2014, 24, 3242-3250.	2.3	51
167	Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer?. Radiotherapy and Oncology, 2009, 91, 95-100.	0.3	50
168	Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta OncolÃ³gica, 2013, 52, 1257-1271.	0.8	50
169	Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunology, Immunotherapy, 2016, 65, 327-339.	2.0	50
170	Fluorine 18 fluorodeoxyglucose positron emission tomography in the diagnosis and follow-up of three patients with vasculitis. American Journal of Medicine, 2004, 116, 50-53.	0.6	49
171	Pretargeted ¹⁷⁷Lu Radioimmunotherapy of Carcinoembryonic Antigenâ€“Expressing Human Colonic Tumors in Mice. Journal of Nuclear Medicine, 2010, 51, 1780-1787.	2.8	49
172	Bevacizumab reduces tumor targeting of antiepidermal growth factor and antiâ€insulinâ€like growth factor 1 receptor antibodies. International Journal of Cancer, 2013, 133, 307-314.	2.3	49
173	The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with ¹⁸F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine, 2016, 57, 1843-1850.	2.8	49
174	Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clinical Pharmacology and Therapeutics, 2005, 78, 52-59.	2.3	48
175	FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Annals of Oncology, 2006, 17, 1650-1655.	0.6	48
176	18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 120-128.	3.3	48
177	Microscopic localization of PEG-liposomes in a rat model of focal infection. Journal of Controlled Release, 2001, 75, 347-355.	4.8	47
178	Annexin A5 Scintigraphy of Forearm as a Novel In Vivo Model of Skeletal Muscle Preconditioning in Humans. Circulation, 2005, 111, 173-178.	1.6	47
179	¹¹¹In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib. Journal of Nuclear Medicine, 2010, 51, 1707-1715.	2.8	47
180	Cost-Effectiveness of FDG-PET/CT for Cytologically Indeterminate Thyroid Nodules: A Decision Analytic Approach. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3263-3274.	1.8	47

#	Article	IF	Citations
181	Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1671-1678.	3.3	47
182	Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1249-1255.	2.2	46
183	ImmunoPET Imaging of Renal Cell Carcinoma with ¹²⁴I- and ⁸⁹Zr-Labeled Anti-CAIX Monoclonal Antibody cG250 in Mice. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 510-515.	0.7	46
184	Targeted Radionuclide and Fluorescence Dual-modality Imaging of Cancer: Preclinical Advances and Clinical Translation. Molecular Imaging and Biology, 2014, 16, 747-755.	1.3	46
185	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology, 2019, 292, 273-286.	3.6	46
186	Synthesis and biological evaluation of potent Î±vÎ²3-integrin receptor antagonists. Nuclear Medicine and Biology, 2006, 33, 953-961.	0.3	45
187	The role of 18F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2037-2047.	3.3	45
188	Dosimetric Analysis of ¹⁷⁷Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on ¹¹¹In-cG250 Imaging. Journal of Nuclear Medicine, 2012, 53, 82-89.	2.8	45
189	Cost-effectiveness of Adding FDG-PET or CT to the Diagnostic Work-up of Patients With Stage III Melanoma. Annals of Surgery, 2012, 255, 771-776.	2.1	45
190	Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. Endocrine Reviews, 2018, 39, 154-191.	8.9	45
191	Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharmaceutical Research, 2000, 17, 600-606.	1.7	44
192	FDG-PET in the Clinically Negative Neck in Oral Squamous Cell Carcinoma. Laryngoscope, 2006, 116, 809-813.	1.1	44
193	Development and Application of Peptide-Based Radiopharmaceuticals. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 543-551.	0.9	44
194	Increased Metabolic Activity of Indolent Liver Metastases After Resection of a Primary Colorectal Tumor. Journal of Nuclear Medicine, 2008, 49, 887-891.	2.8	44
195	Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo. Current Pharmaceutical Design, 2010, 16, 1561-1567.	0.9	44
196	SUV: From Silly Useless Value to Smart Uptake Value. Journal of Nuclear Medicine, 2010, 51, 173-175.	2.8	44
197	Immuno-PET of Cancer: A Revival of Antibody Imaging. Journal of Nuclear Medicine, 2011, 52, 1171-1172.	2.8	44
198	3â€²-Deoxy-3â€²-¹⁸F-Fluorothymidine PETâ€“Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients. Journal of Nuclear Medicine, 2012, 53, 1904-1910.	2.8	44

#	Article	IF	Citations
199	Radiolabelled GLPâ€1 analogues for in vivo targeting of insulinomas. Contrast Media and Molecular Imaging, 2012, 7, 160-166.	0.4	44
200	Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with 111In in HEPES and MES buffer. EJNMMI Research, 2012, 2, 4.	1.1	44
201	Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunology Letters, 2003, 89, 17-24.	1.1	43
202	Two Technetium-99m-Labeled Cholecystokinin-8 (CCK8) Peptides for Scintigraphic Imaging of CCK Receptors. Bioconjugate Chemistry, 2004, 15, 561-568.	1.8	43
203	Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 226-234.	3.3	43
204	FDG-PET in colorectal cancer. Cancer Imaging, 2006, 6, S71-S81.	1.2	41
205	A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats. Annals of Surgical Oncology, 2007, 14, 3274-3282.	0.7	41
206	Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1377-1383.	3.3	41
207	Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clinical Cancer Research, 2003, 9, 3953S-60S.	3.2	41
208	A Novel Animal Model to Evaluate Oxygen Derived Free Radical Damage in Soft Tissue. Free Radical Research, 1997, 26, 363-372.	1.5	40
209	Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1447-1449.	3.3	40
210	[18F]Fluoro-2-deoxy-d-glucose Positron Emission Tomography Detects Gastric Carcinoma in an Early Stage in an Asymptomatic E-Cadherin Mutation Carrier. Clinical Cancer Research, 2004, 10, 6456-6459.	3.2	40
211	Diagnosis of Candida lung abscesses by 18F-fluorodeoxyglucose positron emission tomography. Clinical Microbiology and Infection, 2005, 11, 493-495.	2.8	40
212	Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response. Clinical Cancer Research, 2005, 11, 7178s-7186s.	3.2	40
213	Targeting of a CCK2 receptor splice variant with 111In-labelled cholecystokinin-8 (CCK8) and 111In-labelled minigastrin. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 386-392.	3.3	40
214	Indium-111-Labeled Human Nonspecific Immunoglobulin G: A New Radiopharmaceutical for Imaging Infectious and Inflammatory Foci. Clinical Infectious Diseases, 1992, 14, 1110-1118.	2.9	39
215	Evaluation of Image Registration in PET/CT of the Liver and Recommendations for Optimized Imaging. Journal of Nuclear Medicine, 2007, 48, 910-919.	2.8	39
216	New targeted probes for radioimaging of angiogenesis. Methods, 2009, 48, 188-192.	1.9	39

#	Article	IF	Citations
217	Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507. Clinical Cancer Research, 2011, 17, 7693-7703.	3.2	39
218	Imaging of infection in rabbits with radioiodinated interleukin-1 (Î± and Î²), its receptor antagonist and a chemotactic peptide: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 347-352.	3.3	38
219	Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin Î±_vÎ²₃. Journal of Nuclear Medicine, 2016, 57, 467-472.	2.8	38
220	Effects of Coligand Variation on the In Vivo Characteristics of Tc-99m-Labeled Interleukin-8 in Detection of Infection. Bioconjugate Chemistry, 2002, 13, 370-377.	1.8	37
221	Fluorinated amino acids for tumour imaging with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 834-834.	3.3	37
222	Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 963-968.	1.1	37
223	Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors. Molecular Imaging, 2015, 14, 7290.2015.00015.	0.7	37
224	18F-fluorodeoxyglucose positron-emission tomography combined with computed tomography as a diagnostic tool in native valve endocarditis. Nuclear Medicine Communications, 2018, 39, 747-752.	0.5	37
225	The uptake mechanisms of inflammation-and infection-localizing agents. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 459-465.	2.2	36
226	Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 535-546.	3.3	36
227	Improved Tumor Targeting of Radiolabeled RGD Peptides Using Rapid Dose Fractionation. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 399-404.	0.7	36
228	State-of-the-art uroradiologic imaging in the diagnosis of prostate cancer. Acta OncolÃ³gica, 2011, 50, 25-38.	0.8	36
229	Imaging integrin alphaâ€vâ€betaâ€3 expression in tumors with an ¹⁸Fâ€labeled dimeric RGD peptide. Contrast Media and Molecular Imaging, 2013, 8, 238-245.	0.4	36
230	18F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1181-1188.	3.3	35
231	Quantitative Assessment of Heterogeneity in Tumor Metabolism Using FDG-PET. International Journal of Radiation Oncology Biology Physics, 2012, 82, e725-e731.	0.4	35
232	Optimization of IGF-1R SPECT/CT Imaging Using ¹¹¹In-Labeled F(abâ€²)₂ and Fab Fragments of the Monoclonal Antibody R1507. Molecular Pharmaceutics, 2012, 9, 2314-2321.	2.3	35
233	SPECT- and Fluorescence Imageâ€“Guided Surgery Using a Dual-Labeled Carcinoembryonic Antigenâ€“Targeting Antibody. Journal of Nuclear Medicine, 2014, 55, 1519-1524.	2.8	35
234	Dosimetry in clinical radionuclide therapy: the devil is in the detail. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1-3.	3.3	35

#	Article	IF	Citations
235	Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 759-767.	3.3	35
236	Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. International Journal of Cancer, 2003, 106, 965-972.	2.3	34
237	Anti-CEA Antibody Fragments Labeled with [18F]AlF for PET Imaging of CEA-Expressing Tumors. Bioconjugate Chemistry, 2014, 25, 335-341.	1.8	34
238	99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. Journal of Nuclear Medicine, 2007, 48, 337-43.	2.8	34
239	Technetium-99m labelled hydrazinonicotinamido human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 414-421.	2.2	33
240	Labeling proteins with Tc-99m via hydrazinonicotinamide (HYNIC): optimization of the conjugation reaction. Nuclear Medicine and Biology, 2000, 27, 599-604.	0.3	33
241	Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. Nuclear Medicine Communications, 2010, 31, 938-944.	0.5	33
242	Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1593-602.	3.3	33
243	Diagnostic value of FDG-PET/(CT) in children with fever of unknown origin and unexplained fever during immune suppression. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1916-1923.	3.3	33
244	Multimodality Imaging to Predict Response to Systemic Treatment in Patients with Advanced Colorectal Cancer. PLoS ONE, 2015, 10, e0120823.	1.1	33
245	Targeting human prostate cancer with ¹¹¹Inâ€labeled D2B IgG, F(abâ€²)₂ and Fab fragments in nude mice with PSMAâ€expressing xenografts. Contrast Media and Molecular Imaging, 2015, 10, 28-36.	0.4	33
246	Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. Expert Opinion on Drug Delivery, 2018, 15, 185-196.	2.4	33
247	Writer's cramp: Restoration of striatal D2-binding after successful biofeedback-based sensorimotor training. Parkinsonism and Related Disorders, 2007, 13, 170-173.	1.1	32
248	The Role of FDG-PET in the Selection of Patients with Colorectal Liver Metastases. Annals of Surgical Oncology, 2007, 14, 771-779.	0.7	32
249	mTOR Inhibition Promotes TTF1-Dependent Redifferentiation and Restores Iodine Uptake in Thyroid Carcinoma Cell Lines. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1368-E1375.	1.8	32
250	Assessing the Response to Targeted Therapies in Renal Cell Carcinoma: Technical Insights and Practical Considerations. European Urology, 2014, 65, 766-777.	0.9	32
251	Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients. PLoS ONE, 2015, 10, e0117745.	1.1	32
252	From anatomical to biological target volumes: the role of PET in radiation treatment planning. Cancer Imaging, 2006, 6, S107-S116.	1.2	31

#	Article	IF	Citations
253	The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin Dâ€deficient HIVâ€1â€infected patients. HIV Medicine, 2008, 9, 771-779.	1.0	31
254	Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 915-924.	3.3	31
255	Tyrosine Kinase Inhibitor Sorafenib Decreases ¹¹¹In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma. Journal of Nuclear Medicine, 2014, 55, 242-247.	2.8	31
256	Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric ¹⁸F-FDG PET Images in Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2016, 57, 1033-1039.	2.8	31
257	Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. Journal of Nuclear Medicine, 2005, 46, 495-501.	2.8	31
258	Optimised PET reconstruction of the head and neck area: improved diagnostic accuracy. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1276-1282.	3.3	30
259	Controversies in the Management of Colorectal Liver Metastases: Role of PET and PET/CT. Digestive Surgery, 2008, 25, 413-420.	0.6	30
260	Using the NEMA NU 4 PET Image Quality Phantom in Multipinhole Small-Animal SPECT. Journal of Nuclear Medicine, 2011, 52, 1646-1653.	2.8	30
261	Modelling and simulation of the influence of acute and chronic hypoxia on [¹⁸F]fluoromisonidazole PET imaging. Physics in Medicine and Biology, 2012, 57, 1675-1684.	1.6	30
262	Imaging Experimental Intraabdominal Abscesses With 99mTc-PEG Liposomes and 99mTc-HYNIC IgG. Annals of Surgery, 1999, 229, 551-557.	2.1	30
263	Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 212-219.	2.2	29
264	Pro-inflammatory cytokines in lung and blood during steroid-induced Pneumocystis carinii pneumonia in rats. Journal of Leukocyte Biology, 1996, 60, 710-715.	1.5	29
265	Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPAâ€“Enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate. Journal of Nuclear Medicine, 2009, 50, 1777-1784.	2.8	29
266	Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody. Journal of Nuclear Medicine, 2011, 52, 1601-1607.	2.8	29
267	Localizing chronic Q fever: a challenging query. BMC Infectious Diseases, 2013, 13, 413.	1.3	29
268	Bone scintigraphy after osteochondral autograft transplantation in the knee. Monthly Notices of the Royal Astronomical Society: Letters, 2010, 81, 206-210.	1.2	28
269	Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. Targeted Oncology, 2014, 9, 339-347.	1.7	28
270	Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2Ã—Anti-HSG Bispecific Antibody and a ¹⁷⁷Lu-Labeled Peptide. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 323-329.	0.7	28

#	Article	IF	Citations
271	Cardiovascular and thrombogenic risk of decidual vasculopathy in preeclampsia. American Journal of Obstetrics and Gynecology, 2014, 210, 545.e1-545.e6.	0.7	28
272	Radioimmunoconjugates in the detection of infection and inflammation. Seminars in Nuclear Medicine, 1993, 23, 148-164.	2.5	27
273	Detection of pacemaker and lead infection with FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1245-1245.	3.3	27
274	Prospects in radionuclide imaging of prostate cancer. Prostate, 2012, 72, 1262-1272.	1.2	27
275	Imaging-Based Treatment Adaptation in Radiation Oncology. Journal of Nuclear Medicine, 2015, 56, 1922-1929.	2.8	27
276	Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma. BMC Cancer, 2017, 17, 208.	1.1	27
277	Hip and knee arthroplasty infection: In-111 -IgG scintigraphy in 102 cases. Acta Orthopaedica, 1997, 68, 332-336.	1.4	26
278	Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1828-1835.	3.3	26
279	The Value of ¹⁸F-FDG PET/CT in Diagnosis and During Follow-up in 273 Patients with Chronic Q Fever. Journal of Nuclear Medicine, 2018, 59, 127-133.	2.8	26
280	Different behaviour of radioiodinated human recombinant interleukin-1 and its receptor antagonist in an animal model of infection. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1531-1535.	2.2	25
281	Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-Labeled hLL2 (Epratuzumab) in Nude Mice with CD22-Positive Lymphoma. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 525-533.	0.7	25
282	Colorectal cancer: the role of PET/CT in recurrence. Cancer Imaging, 2005, 5, S143-S149.	1.2	25
283	Level of Fluorodeoxyglucose Uptake Predicts Risk for Recurrence in Melanoma Patients Presenting With Lymph Node Metastases. Annals of Surgical Oncology, 2006, 13, 919-926.	0.7	25
284	Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations. Cancer Imaging, 2007, 7, 77-83.	1.2	25
285	Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer. Cancer Research, 2014, 74, 6216-6223.	0.4	25
286	Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer. PET Clinics, 2015, 10, 345-360.	1.5	25
287	Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 848-857.	3.3	25
288	Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. Cancer Chemotherapy and Pharmacology, 2015, 76, 957-967.	1.1	25

#	Article	IF	Citations
289	^{99m}Tc-CXCL8 SPECT to Monitor Disease Activity in Inflammatory Bowel Disease. Journal of Nuclear Medicine, 2016, 57, 398-403.	2.8	25
290	Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clinical Cancer Research, 2003, 9, 3995S-4002S.	3.2	25
291	Effect of subtotal colectomy on gastric emptying of a solid meal in slow-transit constipation. Diseases of the Colon and Rectum, 2001, 44, 1189-1195.	0.7	24
292	Stabilized ¹¹¹In-Labeled sCCK8 Analogues for Targeting CCK2-Receptor Positive Tumors: Synthesis and Evaluation. Bioconjugate Chemistry, 2010, 21, 663-670.	1.8	24
293	Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: a pilot study. Cardiovascular Diabetology, 2012, 11, 124.	2.7	24
294	Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1858-1867.	3.3	24
295	Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media and Molecular Imaging, 2014, 9, 237-245.	0.4	24
296	Influence of experience and qualification on PET-based target volume delineation. Strahlentherapie Und Onkologie, 2014, 190, 555-562.	1.0	24
297	Imaging Integrin Î±_vÎ²₃ on Blood Vessels with ¹¹¹In-RGD₂ in Head and Neck Tumor Xenografts. Journal of Nuclear Medicine, 2014, 55, 281-286.	2.8	24
298	HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. Clinical Cancer Research, 2018, 24, 1853-1865.	3.2	24
299	Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. Journal of Nuclear Medicine, 2003, 44, 1690-9.	2.8	24
300	Scintigraphic detection of acute experimental endocarditis with the technetium-99m labelled glycoprotein IIb/IIIa receptor antagonist DMP444. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 392-399.	3.3	23
301	Discriminating infection from sterile inflammation: can radiolabelled antibiotics solve the problem?. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 151-152.	3.3	23
302	Bone SPECT reduces the number of unnecessary mandibular resections in patients with squamous cell carcinoma. Oral Oncology, 2006, 42, 409-414.	0.8	23
303	Radiolabeled antibodies in renal cell carcinoma. Cancer Imaging, 2007, 7, 179-188.	1.2	23
304	Histopathologic Validation of 3â€²-Deoxy-3â€²-¹⁸F-Fluorothymidine PET in Squamous Cell Carcinoma of the Oral Cavity. Journal of Nuclear Medicine, 2010, 51, 713-719.	2.8	23
305	The Use of FDG-PET/CT in Patients With Febrile Neutropenia. Seminars in Nuclear Medicine, 2013, 43, 340-348.	2.5	23
306	Optical Imaging of Renal Cell Carcinoma with Antiâ€“Carbonic Anhydrase IX Monoclonal Antibody Girentuximab. Journal of Nuclear Medicine, 2014, 55, 1035-1040.	2.8	23

#	Article	IF	Citations
307	In Vivo Characterization of 4 ⁶⁸Ga-Labeled Multimeric RGD Peptides to Image Î±_vÎ²₃ Integrin Expression in 2 Human Tumor Xenograft Mouse Models. Journal of Nuclear Medicine, 2018, 59, 1296-1301.	2.8	23
308	Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. Journal of Nuclear Medicine, 2006, 47, 1867-74.	2.8	23
309	Leukocytes in Complex Regional Pain Syndrome Type I. Inflammation, 2006, 29, 182-186.	1.7	22
310	Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene. European Heart Journal, 2007, 28, 1085-1091.	1.0	22
311	Review:Intracavitary Radioimmunotherapy to Treat Solid Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 92-107.	0.7	22
312	Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. Nuclear Medicine Communications, 2008, 29, 636-641.	0.5	22
313	In-depth evaluation of the cycloadditionâ€“retro-Dielsâ€“Alder reaction for in vivo targeting with [111In]-DTPA-RGD conjugates. Nuclear Medicine and Biology, 2009, 36, 749-757.	0.3	22
314	Clinical applications of positron emission tomography in sarcoma management. Expert Review of Anticancer Therapy, 2011, 11, 195-204.	1.1	22
315	Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Research, 2012, 2, 5.	1.1	22
316	111In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1430-1438.	3.3	22
317	Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiology Imaging Cancer, 2021, 3, e210048.	0.7	22
318	Pharmacokinetics and Tumor Targeting of ¹³¹I-Labeled F(ab')₂ Fragments of the Chimeric Monoclonal Antibody G250: Preclinical and Clinical Pilot Studies. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 466-477.	0.7	22
319	[18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1970-1984.	3.3	22
320	Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases. Expert Review of Anticancer Therapy, 2004, 4, 607-613.	1.1	21
321	Tumor Accumulation of Radiolabeled Bevacizumab due to Targeting of Cell- and Matrix-Associated VEGF-A Isoforms. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 195-200.	0.7	21
322	In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cellular and Molecular Life Sciences, 2013, 70, 2237-2257.	2.4	21
323	Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250. Journal of Urology, 2015, 194, 532-538.	0.2	21
324	Report of the 6th International Workshop on PET in lymphoma. Leukemia and Lymphoma, 2017, 58, 2298-2303.	0.6	21

#	Article	IF	Citations
325	The effect of molecular weight on nonspecific accumulation of 99mT-labeled proteins in inflammatory foci. Nuclear Medicine and Biology, 2001, 28, 401-408.	0.3	20
326	Interferons Can Upregulate the Expression of the Tumor Associated Antigen G250-MN/CA IX, a Potential Target for (Radio)Immunotherapy of Renal Cell Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 539-547.	0.7	20
327	Striatal dopamine and learning strategyâ€"an 123I-FP-CIT SPECT study. Neuropsychologia, 2004, 42, 1071-1078.	0.7	20
328	Gadopentetate Dimeglumine and FDG Uptake in Liver Metastases of Colorectal Carcinoma as Determined with MR Imaging and PET. Radiology, 2005, 237, 181-188.	3.6	20
329	Noninvasive monitoring of colonic carcinogenesis: feasibility of [18F]FDG-PET in the azoxymethane model. Nuclear Medicine and Biology, 2006, 33, 245-248.	0.3	20
330	Radionuclide Therapy of Cancer with Radiolabeled Antibodies. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 335-343.	0.9	20
331	Gastroparesis in patients with inactive Crohn's disease: a case series. BMC Gastroenterology, 2007, 7, 11.	0.8	20
332	Timing of Adjuvant Radioimmunotherapy after Cytoreductive Surgery in Experimental Peritoneal Carcinomatosis of Colorectal Origin. Annals of Surgical Oncology, 2007, 14, 533-540.	0.7	20
333	Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(abâ€²)2 antibody. Cancer, 2010, 116, 1111-1117.	2.0	20
334	Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination. OncoImmunology, 2013, 2, e24661.	2.1	20
335	Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. International Journal of Cancer, 2014, 135, 2770-2782.	2.3	20
336	Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer. Current Opinion in Pulmonary Medicine, 2015, 21, 314-321.	1.2	20
337	Effectiveness of an 18F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. Radiotherapy and Oncology, 2016, 118, 251-256.	0.3	20
338	Soft Tissue Repair Capacity after Oxygen-Derived Free Radical-Induced Damage in One Hindlimb of the Rat. Journal of Surgical Research, 1997, 72, 60-69.	0.8	19
339	Prognostic Value of Different Metabolic Measurements with Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Resectable Non-Small Cell Lung Cancer: A Two-Center Study. Journal of Thoracic Oncology, 2007, 2, 1007-1012.	0.5	19
340	FDG-PET/CT can visualise the extent of inflammation in rheumatoid arthritis of the tarsus. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 439-439.	3.3	19
341	Preclinical Evaluation of ⁶⁸ Ga-DOTA-Minigastrin for the Detection of Cholecystokinin-2/Gastrin Receptor-Positive Tumors. Molecular Imaging, 2011, 10, 7290.2010.00032.	0.7	19
342	In Vivo Tracking Techniques for Cellular Regeneration, Replacement, and Redirection. Journal of Nuclear Medicine, 2012, 53, 1825-1828.	2.8	19

#	Article	IF	Citations
343	The impact of respiratory gated positron emission tomography on clinical staging and management of patients with lung cancer. Lung Cancer, 2015, 90, 217-223.	0.9	19
344	Molecular Imaging and Theranosticsâ€"A Multidisciplinary Approach. Seminars in Nuclear Medicine, 2019, 49, 247-254.	2.5	19
345	Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2174-2188.	3.3	19
346	Scintigraphic imaging using 99m Tc-labeled PEG liposomes allows early detection of experimental invasive pulmonary aspergillosis in neutropenic rats. Nuclear Medicine and Biology, 2002, 29, 177-184.	0.3	18
347	ORGAN DAMAGE IS PRECEDED BY CHANGES IN PROTEIN EXTRAVASATION IN AN EXPERIMENTAL MODEL OF MULTIPLE ORGAN DYSFUNCTION SYNDROME. Shock, 1997, 7, 98-104.	1.0	17
348	In Vivo Efficacy of Trovafloxacin against Bacteroides fragilis in Mixed Infection with either Escherichia coli or a Vancomycin-Resistant Strain of Enterococcus faecium in an Established-Abscess Murine Model. Antimicrobial Agents and Chemotherapy, 2001, 45, 1394-1401.	1.4	17
349	FDG-PET in infectious and inflammatory disease. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1568-1570.	3.3	17
350	99m Tc-Labeled Interleukin-8 for Scintigraphic Detection of Pulmonary Infections. Chest, 2004, 126, 1954-1961.	0.4	17
351	PET imaging of infection with a HYNIC-conjugated LTB4 antagonist labeled with F-18 via hydrazone formation. Nuclear Medicine and Biology, 2007, 34, 691-695.	0.3	17
352	FDG-PET/CT based response-adapted treatment. Cancer Imaging, 2012, 12, 324-335.	1.2	17
353	Pretargeted ImmunoPET of Prostate Cancer with an Anti-TROP-2 x Anti-HSG Bispecific Antibody in Mice with PC3 Xenografts. Molecular Imaging and Biology, 2015, 17, 94-101.	1.3	17
354	Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy. Radiotherapy and Oncology, 2016, 119, 473-479.	0.3	17
355	Guidelines for quality control of PET/CT scans in a multicenter clinical study. EJNMMI Physics, 2017, 4, 23.	1.3	17
356	A bivalent leukotriene B(4) antagonist for scintigraphic imaging of infectious foci. Journal of Nuclear Medicine, 2003, 44, 1087-91.	2.8	17
357	Kinetics of 99mTc-labeled interleukin-8 in experimental inflammation and infection. Journal of Nuclear Medicine, 2003, 44, 1502-9.	2.8	17
358	Retention of technetium-99m in infectious foci in rats after release from technetium-99m labelled human non-specific polyclonal immunoglobulin G: A dual-label study with hydrazinonicotinamido and iminothiolano immunoglobulin. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1536-1539.	2.2	16
359	Positive Positron Emission Tomography Scan in Sarcoidosis and Two Challenging Cases of Metastatic Cancer. Journal of Clinical Oncology, 2005, 23, 8906-8907.	0.8	16
360	Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND). European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 413-421.	3.3	16

#	Article	IF	Citations
361	Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. Nuclear Medicine Communications, 2009, 30, 550-557.	0.5	16
362	Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET. Clinical Colorectal Cancer, 2011, 10, E1-E5.	1.0	16
363	Characterization and optimization of image quality as a function of reconstruction algorithms and parameter settings in a Siemens Inveon small-animal PET scanner using the NEMA NU 4-2008 standards. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2011, 629, 357-367.	0.7	16
364	Can ¹¹¹In-RGD₂ Monitor Response to Therapy in Head and Neck Tumor Xenografts?. Journal of Nuclear Medicine, 2014, 55, 1849-1855.	2.8	16
365	Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Nonâ€“Small Cell Lung Cancer by Using Dynamic ¹⁸F Fluorodeoxyglucose PET. Radiology, 2017, 283, 547-559.	3.6	16
366	18F-FDG PET/CT in Local Ablative Therapies: A Systematic Review. Journal of Nuclear Medicine, 2018, 59, 551-556.	2.8	16
367	PET/CT: panacea, redundancy, or something in between?. Journal of Nuclear Medicine, 2004, 45 Suppl 1, 15S-24S.	2.8	16
368	Impact of Ge-68â•Ga-68-based versus CT-based attenuation correction on PET. Medical Physics, 2007, 34, 889-897.	1.6	15
369	Multimodality Probes: Amphibian Cars for Molecular Imaging. Journal of Nuclear Medicine, 2008, 49, 1213-1214.	2.8	15
370	Imaging of HIV-Associated Kaposi Sarcoma; F-18-FDG-PET/CT and In-111-Bevacizumabscintigraphy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 444-446.	0.9	15
371	Nuclear Medicine Imaging of Infection in Cancer Patients (With Emphasis on FDG-PET). Oncologist, 2011, 16, 980-991.	1.9	15
372	Correlation between tumor oxygenation and18F-fluoromisonidazole PET data simulated based on microvessel images. Acta OncolÃ³gica, 2013, 52, 1308-1313.	0.8	15
373	Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation. Cancers, 2021, 13, 4346.	1.7	15
374	Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1342-1343.	3.3	14
375	Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination. Nuclear Medicine and Biology, 2006, 33, 453-458.	0.3	14
376	Pulmonary Sclerosing Hemangioma Detected by Fluorodeoxyglucose Positron Emission Tomography in Familial Adenomatous Polyposis: Report of a Case. Diseases of the Colon and Rectum, 2007, 50, 1987-1991.	0.7	14
377	Exercise-induced Changes in Venous Vascular Function in Nonpregnant Formerly Preeclamptic Women. Reproductive Sciences, 2009, 16, 414-420.	1.1	14
378	Radioimmunotherapy Improves Survival of Rats with Microscopic Liver Metastases of Colorectal Origin. Annals of Surgical Oncology, 2009, 16, 2065-2073.	0.7	14

#	Article	IF	Citations
379	Tc-99m-PEG-Liposomes Target Both Adhesions and Abscesses and Their Reduction by Hyaluronate in Rats With Fecal Peritonitis. Journal of Surgical Research, 2009, 154, 246-251.	0.8	14
380	Scanning multiple mice in a small-animal PET scanner: Influence on image quality. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2010, 621, 605-610.	0.7	14
381	Unexplained first trimester recurrent pregnancy loss and low venous reserves. Human Reproduction, 2012, 27, 2613-2618.	0.4	14
382	Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma. Immunotherapy, 2013, 5, 489-495.	1.0	14
383	Demineralized Bone Matrix-Induced Ectopic Bone Formation in Rats: In Vivo Study with Follow-up by Magnetic Resonance Imaging, Magnetic Resonance Angiography, and Dual-Energy X-Ray Absorptiometry. Tissue Engineering, 2004, 10, 747-754.	4.9	13
384	Pharmacokinetics and Tumor Targeting of 131I-Labeled F(ab9)2 Fragments of the Chimeric Monoclonal Antibody G250: Preclinical and Clinical Pilot Studies. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 466-477.	0.7	13
385	Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma and Normal Tissues: Experiences From (Radio) Immunotherapy. Journal of Clinical Oncology, 2008, 26, 3808-3809.	0.8	13
386	Immunotherapy response evaluation with 18F-FDG-PET in patients with advanced stage renal cell carcinoma. World Journal of Urology, 2013, 31, 841-846.	1.2	13
387	Comparison of a Free-Breathing CT and an Expiratory Breath-Hold CT with Regard to Spatial Alignment of Amplitude-Based Respiratory-Gated PET and CT Images. Journal of Nuclear Medicine Technology, 2014, 42, 269-273.	0.4	13
388	The Predictive Value of Early In-Treatment ¹⁸F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2017, 58, 1243-1248.	2.8	13
389	PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).. Journal of Clinical Oncology, 2014, 32, 11001-11001.	0.8	13
390	Role of FDG-PET in the diagnosis and management of lung cancer. Expert Review of Anticancer Therapy, 2004, 4, 561-567.	1.1	12
391	Combination Therapy Using Gemcitabine and Radioimmunotherapy in Nude Mice with Small Peritoneal Metastases of Colonic Origin. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 506-514.	0.7	12
392	The Relation Between Venous Reserve Capacity and Low Plasma Volume. Reproductive Sciences, 2008, 15, 604-612.	1.1	12
393	Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice. Cancer Imaging, 2008, 8, S61-S68.	1.2	12
394	Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer. Journal of Nuclear Medicine, 2012, 53, 1926-1932.	2.8	12
395	International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection. Nephron, 2016, 134, 205-214.	0.9	12
396	Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy. European Journal of Cancer, 2017, 77, 127-139.	1.3	12

#	Article	IF	Citations
397	Prognostic Value of Head and Neck Tumor Proliferative Sphericity From 3â€™-Deoxy-3â€™-[¹⁸F] Fluorothymidine Positron Emission Tomography. IEEE Transactions on Radiation and Plasma Medical Sciences, 2018, 2, 33-40.	2.7	12
398	Preclinical evaluation of 68Ga-DOTA-minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors. Molecular Imaging, 2011, 10, 144-52.	0.7	12
399	Assessment of prosthetic vascular graft thrombogenicity using the technetium-99m labeled glycoprotein IIb/IIIa receptor antagonist DMP444 in a dog model. Vascular, 2002, 10, 566-569.	0.5	11
400	Evaluation of Tc-99mâ€“Labeled Glycoprotein IIb/IIIa Receptor Antagonist DMP444 SPECT in Patients with Infective Endocarditis. Clinical Nuclear Medicine, 2003, 28, 480-484.	0.7	11
401	Nuclear medicine imaging and therapy of neuroendocrine tumours. Cancer Imaging, 2006, 6, S178-S184.	1.2	11
402	18F-FDG and 18F-FLT Do Not Discriminate Between Reactive and Metastatic Lymph Nodes in Oral Cancer. Journal of Nuclear Medicine, 2009, 50, 490-491.	2.8	11
403	Optimizing Lutetium 177â€“Antiâ€“Carbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model. Molecular Imaging, 2014, 13, 7290.2014.00008.	0.7	11
404	Nuclear medicine theranostics comes of age. Lancet Oncology, The, 2021, 22, 1497-1498.	5.1	11
405	Ability of FDG-PET to detect all cancers in patients with familial adenomatous polyposis, and impact on clinical management. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 270-274.	3.3	10
406	Adjuvant Radioimmunotherapy Improves Survival of Rats After Resection of Colorectal Liver Metastases. Annals of Surgery, 2011, 253, 336-341.	2.1	10
407	The strength of small: Improved targeting of Insulin-like Growth Factor-1 Receptor (IGF-1R) with F(abâ€²)2-R1507 fragments in Ewing sarcomas. European Journal of Cancer, 2013, 49, 2851-2858.	1.3	10
408	Individualized image-based lymph node irradiation for prostate cancer. Nature Reviews Urology, 2013, 10, 376-385.	1.9	10
409	Preoperative FDG-PET-Scan in Patients with Resectable Colorectal Liver Metastases Does Not Improve Overall Survival: A Retrospective Analyses Stratified by Clinical Risk Score. Digestive Surgery, 2013, 30, 451-458.	0.6	10
410	Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Physics, 2015, 2, 5.	1.3	10
411	Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor. Acta OncolÃ³gica, 2016, 55, 1510-1512.	0.8	10
412	Clinical application of FDG-PET/CT in metastatic infections. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 232-246.	0.4	10
413	Imaging of infection and inflammation with an improved 99mTc-labeled LTB4 antagonist. Journal of Nuclear Medicine, 2005, 46, 1546-51.	2.8	10
414	Localization of Infection in HIV Antibody Positive Patients With Fever Comparison of the Efficacy of Ga-67 Citrate and Radiolabeled Human IgG. Clinical Nuclear Medicine, 1995, 20, 334-339.	0.7	9

#	Article	IF	Citations
415	Lyophilization of TC-99m-Hynic Labeled Peg-Liposomes. Journal of Liposome Research, 2000, 10, 117-129.	1.5	9
416	Biodistribution and Imaging of FDG in Rats with LS174T Carcinoma Xenografts and Focal Escherichia coli Infection. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 310-315.	0.7	9
417	Endotoxin tolerance does not limit mild ischemia-reperfusion injury in humans in vivo. Innate Immunity, 2009, 15, 360-367.	1.1	9
418	Image quality phantom and parameters for high spatial resolution small-animal SPECT. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2011, 654, 539-545.	0.7	9
419	The influence of SPECT reconstruction algorithms on image quality and diagnostic accuracy in phantom measurements and 99mTc-sestamibi parathyroid scintigraphy. Nuclear Medicine Communications, 2014, 35, 64-72.	0.5	9
420	Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18 F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold. European Journal of Cancer, 2016, 56, 54-58.	1.3	9
421	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. Clinical Radiology, 2018, 73, 588-589.	0.5	9
422	Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring. Current Molecular Medicine, 2013, 13, 1506-1522.	0.6	9
423	FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3452-3469.	3.3	9
424	Synthesis of Leukotriene B4 Antagonists Labeled with In-111 or Tc-99m to Image Infectious and Inflammatory Foci. Journal of Medicinal Chemistry, 2005, 48, 6442-6453.	2.9	8
425	FDG-PET in the detection of early pancreatic cancer in a BOP hamster model. Nuclear Medicine and Biology, 2005, 32, 445-450.	0.3	8
426	Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Immunology, Immunotherapy, 2006, 55, 47-55.	2.0	8
427	Nodular Fasciitis on F-18 FDG PET. Clinical Nuclear Medicine, 2010, 35, 830-831.	0.7	8
428	18F-FLT PET changes during radio - therapy combined with cetuximab in head and neck squamous cell carcinoma patients. Nuklearmedizin - NuclearMedicine, 2014, 53, 60-66.	0.3	8
429	Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression. Molecular Pharmaceutics, 2014, 11, 4249-4257.	2.3	8
430	Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of 18F-FDG-PET based tumor segmentation in head and neck squamous cell carcinoma in a multicenter setting. Radiotherapy and Oncology, 2019, 130, 39-45.	0.3	8
431	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. Anticancer Research, 2019, 39, 1309-1316.	0.5	8
432	18F-fluoro-L-thymidine-PET for the evaluation of primary brain tumours in children: a report of three cases. Nuclear Medicine Communications, 2010, 31, 482-487.	0.5	8

#	Article	IF	Citations
433	18F-FDG PET-CTÂin rheumatoid arthritis patients tapering TNFi: reliability, validity and predictive value. Rheumatology, 2022, 61, SI6-SI13.	0.9	8
434	Targeting of Biliary Cancer with Radiolabeled Chimeric Monoclonal Antibody CG250. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 263-268.	0.7	7
435	Effects of hyperoxygenation on FDG-uptake in head-and-neck cancer. Radiotherapy and Oncology, 2006, 80, 51-56.	0.3	7
436	Correction of an image size difference between positron emission tomography (PET) and computed tomography (CT) improves image fusion of dedicated PET and CT. Nuclear Medicine Communications, 2006, 27, 515-519.	0.5	7
437	Hyperthermia and Fibrinolytic Therapy Do Not Improve the Beneficial Effect of Radioimmunotherapy Following Cytoreductive Surgery in Rats with Peritoneal Carcinomatosis of Colorectal Origin. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 301-309.	0.7	7
438	Shortened dynamic FDG-PET protocol to determine the glucose metabolic rate in non-small cell lung carcinoma. , 2008, , .		7
439	Molecular imaging of solid tumors: exploiting the potential. Nature Reviews Clinical Oncology, 2009, 6, 609-611.	12.5	7
440	18 F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with solid tumors. World Journal of Nuclear Medicine, 2012, 11, 65-69.	0.3	7
441	Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. Investigational New Drugs, 2013, 31, 881-890.	1.2	7
442	Comparison of liver SUV using unenhanced CT versus contrast-enhanced CT for attenuation correction in 18F-FDG PET/CT. Nuclear Medicine Communications, 2014, 35, 472-477.	0.5	7
443	Radionuclide imaging of drug delivery for patient selection in targeted therapy. Expert Opinion on Drug Delivery, 2014, 11, 175-185.	2.4	7
444	A Clinical Feasibility Study to Image Angiogenesis in Patients with Arteriovenous Malformations Using ⁶⁸Ga-RGD PET/CT. Journal of Nuclear Medicine, 2020, 61, 270-275.	2.8	7
445	Acute Myelofibrosis Mimicking Multiple Bone Metastases on Tc-99m MDP Bone Imaging. Clinical Nuclear Medicine, 1998, 23, 1-2.	0.7	7
446	Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery. Current Drug Targets, 2015, 16, 625-633.	1.0	7
447	Thrombogenicity and Related Biological Properties of Heparin Bonded Collagen Coated Polyester and Human Umbilical Vein Prosthetic Vascular Grafts. Journal of Surgical Research, 2006, 134, 182-189.	0.8	6
448	Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1266-1272.	3.3	6
449	Extraperitoneal Leakage as a Possible Explanation for Failure of One-Time Intraperitoneal Treatment in Ovarian Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 508-514.	0.7	6
450	[¹⁸F]FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma. Hepatology Research, 2007, 37, 127-132.	1.8	6

#	Article	IF	Citations
451	Bone-marrow uptake of 18F-FDG during fever. Lancet Infectious Diseases, The, 2010, 10, 509-510.	4.6	6
452	¹⁸F-FDG PET/CT for the Detection of Septic Embolisms in Patients with Infectious Endocarditis. Journal of Nuclear Medicine, 2014, 55, 1045-1046.	2.8	6
453	FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment. Nuclear Medicine and Molecular Imaging, 2015, 49, 237-240.	0.6	6
454	18F-FDG PET/CT in Detecting Metastatic Infection in Children. Clinical Nuclear Medicine, 2016, 41, 278-281.	0.7	6
455	Targeted Î±-Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?. Journal of Nuclear Medicine, 2016, 57, 1838-1839.	2.8	6
456	Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside. Journal of Nuclear Medicine, 2016, 57, 996-1001.	2.8	6
457	Response Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases. Molecular Imaging and Biology, 2017, 19, 540-549.	1.3	6
458	Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1864-1870.	3.3	6
459	Sliced alternating DICOM series: convenient visualisation of image fusion on PACS. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 247-248.	3.3	5
460	Regarding Davis et al.: Assessment of 18F PET signals for automatic target volume definition in radiotherapy treatment planning. Radiotherapy and Oncology, 2007, 83, 102-103.	0.3	5
461	Response to comment by Aprile et al.: The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1259-1260.	3.3	5
462	Imaging Infection and Inflammation. , 2006, , 113-126.		5
463	Specific antibody uptake in tuberculosis?. European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 568-569.	2.2	4
464	In vivo Molecular Prediction of Carbonic Anhydrase IX-G250MN Expression on Immunotherapy Outcome in Renal Cancer. Clinical Cancer Research, 2005, 11, 8886-8886.	3.2	4
465	A response to â€˜Nanotechnology and the need for risk governanceâ€™, O. Renn & M.C. Roco, 2006. J. Nanoparticle Research 8(2): 153â€“191. Journal of Nanoparticle Research, 2007, 9, 1217-1220.	0.8	4
466	Contribution of normalization to image noise for the Siemens Inveon small-animal PET scanner. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2009, 605, 433-435.	0.7	4
467	Dynamics of IGF-1R Expression During Endocrine Breast Cancer Treatment. Molecular Imaging and Biology, 2014, 16, 529-37.	1.3	4
468	Brief progress report from the intersocietal working group on differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1345-1347.	3.3	4

#	Article	IF	Citations
469	Abstract OT3-2-01: IMPACT: IMaging PAtients for Cancer drug selecTion â€“ Metastatic breast cancer (MBC). , 2015, , .		4
470	Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules. Endocrine Connections, 2022, 11, .	0.8	4
471	Serial indium-111-labelled IgG biodistribution in ratPneumocystis carinii pneumonia: a tool to monitor the course and severity of the infection. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1129-1132.	2.2	3
472	Solitary skull recurrence from stage I seminomatous germ cell tumor of testis. Urology, 2004, 64, 377-379.	0.5	3
473	Can Antibody Galactosylation Be Used to Improve Radioimmunotherapy of Induced Peritoneal Carcinomatosis of Colonic Origin in the Rat?. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 29-34.	0.7	3
474	False Positive 18F-FDG PET/CT Due to Inflamed Concha Bullosa. Clinical Nuclear Medicine, 2012, 37, 509-510.	0.7	3
475	Insight into the dynamics, localization and magnitude of antigen-specific immune responses by [18F]FLT PET imaging. OncoImmunology, 2012, 1, 744-745.	2.1	3
476	Anakinra Injection Site Reaction on FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, 492-493.	0.7	3
477	Molecular Imaging of Prostate Cancer: Tapping into the Opportunities. Journal of Nuclear Medicine, 2015, 56, 169-170.	2.8	3
478	Vascular infection with outside-in vertebral destruction in chronic Q fever. Lancet Infectious Diseases, The, 2018, 18, 603.	4.6	3
479	Consensus Procedures in Oncological Imaging: The Case of Prostate Cancer. Cancers, 2019, 11, 1788.	1.7	3
480	Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine. Current Pharmaceutical Design, 2014, 20, 2293-2307.	0.9	3
481	Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. Journal of Nuclear Medicine, 2003, 44, 853.	2.8	3
482	A Comparison of Free Radical-Induced Vascular and Skeletal Muscle Damage in Immunocompetent and Neutropenic Rats. Journal of Surgical Research, 1999, 82, 346-352.	0.8	2
483	Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma: Best of Both Worlds?. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 1-5.	0.7	2
484	Tracers to Monitor the Response to Chemotherapy: In Vitro Screening of Four Radiopharmaceuticals. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 457-465.	0.7	2
485	Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by ¹⁸F-FAZA and ¹²⁵I-Gluco-RGD Autoradiography. Journal of Nuclear Medicine, 2008, 49, 1732.1-1732.	2.8	2
486	¹⁸F-2-Deoxy-2-Fluoro-D-Glucose Positron Emission Tomography, Computed Tomography, and Magnetic Resonance Imaging for the Detection of Experimental Colorectal Liver Metastases. Molecular Imaging, 2012, 11, 7290.2011.00035.	0.7	2

#	Article	IF	Citations
487	Immuno-PET in Pontine Glioma: More Than Meets the Eye?. Journal of Nuclear Medicine, 2018, 59, 610-611.	2.8	2
488	EANM commitment towards involvement and engagement of patients and the public: learning from the UK experience. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2218-2219.	3.3	2
489	Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study).. Journal of Clinical Oncology, 2018, 36, 11555-11555.	0.8	2
490	Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. Anticancer Research, 2015, 35, 5601-6.	0.5	2
491	FDG-PET as a clinical tool in differentiation between pancreatic carcinoma and chronic pancreatitis. Gastroenterology, 2003, 124, A632.	0.6	1
492	Title is missing!. Clinical Nuclear Medicine, 2003, 28, 480-484.	0.7	1
493	Time to target evaluation criteria of targeted therapies. Nuclear Medicine Communications, 2009, 30, 487-489.	0.5	1
494	Shortened Dynamic ¹⁸F-FDG PET. Journal of Nuclear Medicine, 2011, 52, 1330.1-1330.	2.8	1
495	Reply to comment by Treglia and Bertagna: FDG PET/CT for detection of infectious endocarditis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1114-1115.	3.3	1
496	Preclinical Studies of SPECT and PET Tracers for NET. PET Clinics, 2014, 9, 63-69.	1.5	1
497	Sterically Stabilized Liposomes to Image Infection and Inflammation. , 1998, , 229-240.		1
498	Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.. Blood, 2006, 108, 2400-2400.	0.6	1
499	Tumor hypoxia as a mechanism of resistance to bevacizumab in a murine model.. Journal of Clinical Oncology, 2012, 30, e13111-e13111.	0.8	1
500	Toward Improved Outcomes for Patients With Lung Cancer Globally: The Essential Role of Radiology and Nuclear Medicine. JCO Global Oncology, 2022, , .	0.8	1
501	Macrophage targeting in experimental arthritis. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 727-727.	2.2	0
502	Peritoneal Carcinomatosis of Colorectal Origin: Standard of Care. Annals of Surgery, 2006, 244, 633-634.	2.1	0
503	358 POSTER 18F-FLT-PET for the evaluation of MEK inhibitor AZD6244. European Journal of Cancer, Supplement, 2008, 6, 113.	2.2	0
504	EFFECT OF SORAFENIB (NEXAVARÂ®) ON IMAGING OF CLEAR CELL RENAL CELL CARCINOMA USING 111-INDIUM LABELLED BEVACIZUMAB (AVASTINÂ®). European Urology Supplements, 2008, 7, 306.	0.1	0

#	Article	IF	Citations
505	Reply: Increased Metabolic Activity of Indolent Liver Metastases After Resection of a Primary Colorectal Tumor. Journal of Nuclear Medicine, 2009, 50, 168.1-168.	2.8	0
506	Correlation of Segmented Metabolic Tumor Volume with Outcome - Letter. Clinical Cancer Research, 2010, 16, 1968-1968.	3.2	0
507	PL - 92. Non-invasive determination of the beta cell mass in rats by SPECT with In-111-DTPA-Exendin-3. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 154-155.	0.0	0
508	Reply to John Samuel Banerji's Letter to the Editor re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111â€“Labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma. Eur Urol 2013;63:1101â€“6. European Urology, 2013, 64, e83.	0.9	0
509	Contributions of multimodal imaging. Cancer Imaging, 2014, 14, .	1.2	0
510	European Association of Nuclear Medicine: adapt the present, shape the future. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 590-591.	3.3	0
511	Recurrent Laryngeal Carcinoma Pet Study (Relaps): Cost Analysis Of 18f-Fdg Pet In Patients With Suspected Recurrent Laryngeal Cancer Previously Treated With Radiotherapy. Value in Health, 2015, 18, A353.	0.1	0
512	In response to â€œHistopathologic validation of 3â€²-deoxy-3â€²-18F-fluorothymidine PET for detecting tumour repopulation during fractionated radiotherapy in human FaDu squamous cell carcinoma in nude miceâ€• Radiotherapy and Oncology, 2015, 114, 417-418.	0.3	0
513	A5.03â€…Monitoring therapy response of experimental arthritis with radiolabeled tracers targeting fibroblasts, macrophages or integrin Î±_vÎ²₃. Annals of the Rheumatic Diseases, 2016, 75, A42.1-A42.	0.5	0
514	Molecular Imaging of Infection and Inflammation. , 2003, , 233-251.		0
515	Nuclear Medicine in the Assessment of Painful Joint Prostheses. , 2012, , 561-581.		0
516	The effect of bevacizumab on targeting of anti-epidermal growth factor receptor and anti-insulin-like growth factor 1 receptor antibodies.. Journal of Clinical Oncology, 2012, 30, 3035-3035.	0.8	0
517	Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, e14014-e14014.	0.8	0
518	FDG-PET/CT Limited to the Thorax and Upper Abdomen for Staging and Management of Lung Cancer. PLoS ONE, 2016, 11, e0160539.	1.1	0
519	Infectie en ontsteking. , 2017, , 579-604.		0